A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Depressive episodes are a major cause of morbidity and dysfunction in individuals suffering from bipolar disorder. Currently available treatments for this condition have limited efficacy and new therapeutic options are needed. Extensive research in the pathophysiology of bipolar disorder points to the existence of mitochondrial and bioenergetic dysfunction. We hypothesized that creatine monohydrate, a nutraceutical that works as a mitochondrial modulator, would be effective as an adjunctive therapy for bipolar depression. We conducted a double-blind trial in which 35 patients with bipolar disorder type I or II in a depressive episode by DSM-IV criteria and in use of regular medication for the treatment of this phase of the disease were randomly allocated into two adjunctive treatment groups for 6 weeks: creatine monohydrate 6 g daily (N = 17) or placebo (N = 18). Primary efficacy was assessed by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS). We did not find a statistically significant difference in the comparison between groups for the change in score on the MADRS after 6 weeks in an intention-to-treat (ITT) analysis (p = 0.560; Cohen's d = 0.231). However, we found significant superiority of creatine add-on vs. placebo when we considered the remission criterion of a MADRS score ≤ 12 at week 6 analyzing the outcome of the 35 randomized patients on ITT (52.9% remission in the creatine group vs. 11.1% remission in the placebo group) and of the 23 completers (66.7% remission in the creatine group vs. 18.2% remission in the placebo group) (p = 0.012; OR = 9.0 and p = 0.036; OR = 9.0, respectively). Two patients who received creatine switched to hypomania/mania early in the trial. No clinically relevant physical side-effects were reported or observed. This proof-of-concept study, aiming to restore brain bioenergetics using an adjunctive mitochondrial modulator, is not conclusive on the efficacy of creatine add-on for bipolar depression, but suggests that this compound may have a role in the adjunctive treatment of this phase of the illness. Further investigation through randomized controlled trials with larger samples should be conducted to verify the efficacy of creatine supplementation for bipolar depression and also for subsyndromal depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and, in some instances, improve the efficacy of some anti-depressant medications [5,29,169,170,171,172].”
From Creatine in health and disease (2021) · cites this paper as [172]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, early evidence indicates that creatine may be used as an adjunctive therapy in the actual management of clinical depression [71,72,73].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 6×
“Regarding the two patients who received creatine that were discontinued from the study due to worsening of depression, it is important to note that they did not present significant mixed features at baseline (total scores on YMRS = 0 and 2).”
MethodInfluentialMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950 · cited 1×
“Creatine is a non-essential dietary component found primarily in meat and fish and endogenously produced by the liver, kidneys and pancreas (Wyss and Kaddurah-Daouk 2000).”
BackgroundThe Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder
Rosa, A. R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J., et al. (2007) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-3-5 · Cited by 905
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“Remission was defined as a MADRS score of 12 or less, as it has been defined in important published trials in the field (Calabrese et al. 2005; Loebel et al. 2014; McElroy et al. 2010; Young et al. 2010).”
MethodTohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
Research works printed but not linked: 1
- First MB Spitzer RL Gibbon M Williams Janet BW Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV) 1996 Washington, DC American Psychiatric Press
Cited by
Creatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
Effects of creatine supplementation on brain function and health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojic, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 145
Mitochondrial dysfunction as a critical event in the pathophysiology of bipolar disorder
Scaini, G., Andrews, T., Lima, C. N. D. C., Benevenuto, D., STRECK, E. L., & Quevedo, J. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.12.002 · Cited by 94
Balestrino, M., & Adriano, E. (2019) · Medicinal Research Reviews · doi:10.1002/med.21590 · Cited by 90
Creatine for the Treatment of Depression
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019) · Biomolecules · doi:10.3390/biom9090406 · Cited by 74
“In a more recent study, Toniolo and colleagues [192] randomized 53 patients with BD type I or II who were currently in a depressive episode to 6g of creatine daily or matched placebo for 6 weeks, as an adjunct to their existing medications.”
Creatine Supplementation in Children and Adolescents
Jagim, A. R., & Kerksick, C. M. (2021) · Nutrients · doi:10.3390/nu13020664 · Cited by 61
Nutrition and bipolar disorder: a systematic review
Gabriel, F. C., Oliveira, M., Martella, B. D. M., Berk, M., Brietzke, E., Jacka, F. N., & Lafer, B. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2077031 · Cited by 59
“pared to the placebo group for BD symptoms or weight loss [85,86].”
Self-citationMarshall, R. P., Droste, J.-N., Gießing, J., & Kreider, R. B. (2022) · Nutrients · doi:10.3390/nu14030529 · Cited by 55
Nutraceuticals in Psychiatric Disorders: A Systematic Review
Bozzatello, P., Novelli, R., Montemagni, C., Rocca, P., & Bellino, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094824 · Cited by 36
The Association Among Bipolar Disorder, Mitochondrial Dysfunction, and Reactive Oxygen Species
Kageyama, Y., Okura, S., Sukigara, A., Matsunaga, A., Maekubo, K., Oue, T., Ishihara, K., Deguchi, Y., & Inoue, K. (2025) · Biomolecules · doi:10.3390/biom15030383 · Cited by 36
What is bipolar disorder? A disease model of dysregulated energy expenditure
Mansur, R. B., Lee, Y. L., McIntyre, R. S., & Brietzke, E. M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.006 · Cited by 36
Juneja, K., Bhuchakra, H. P., Sadhukhan, S., Mehta, I., Niharika, A., Thareja, S., Nimmakayala, T., & Sahu, S. (2024) · Cureus · doi:10.7759/cureus.71638 · Cited by 30
A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder
Ashton, M. M., Kavanagh, B. E., Marx, W., Berk, M., Sarris, J. J., Ng, C. H., Hopwood, M., Williams, L. J., & Dean, O. M. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720961734 · Cited by 29
Targeting Mitochondrial Dysfunction for Bipolar Disorder
Kuperberg, M., Greenebaum, S. L. A., & Nierenberg, A. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_152 · Cited by 29
Liang, L., Chen, J., Xiao, L., Wáng, Q., & Wang, G. (2022) · Translational Psychiatry · doi:10.1038/s41398-021-01727-7 · Cited by 29
Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine
Khanra, S., Reddy, P. H., Giménez‐Palomo, A., Park, C. H. J., Panizzutti, B., McCallum, M., Arumugham, S. S., Shreekantiah, U., Debnath, M., Das, B., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02134-8 · Cited by 30
Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder
Machado‐Vieira, R., Courtes, A. C., Zarate, C. A., Henter, I. D., & Manji, H. K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1228455 · Cited by 28
Fusar-Poli, L., Surace, T., Vanella, A., Meo, V., Patania, F., Furnari, R., Signorelli, M. S., & Aguglia, E. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.039 · Cited by 24
Sherpa, N. N., De Giorgi, R., Ostinelli, E. G., Choudhury, A., Dolma, T., & Dorjee, S. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.004 · Cited by 22
Diet and Neurocognition in Mood Disorders - An Overview of the Overlooked
Balanzá‐Martínez, V., Shansis, F., Tatay-Manteiga, A., & López-García, P. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318152530 · Cited by 22
Advances in the psychopharmacotherapy of bipolar disorder type I
Sleem, A., & El‐Mallakh, R. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1893306 · Cited by 16
Nutraceuticals in mood disorders: current knowledge and future directions
Travica, N., Teasdale, S. B., & Marx, W. (2022) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000826 · Cited by 16
de Guingand, D. L., Palmer, K. R., Bilardi, J. E., & Ellery, S. J. (2020) · Midwifery · doi:10.1016/j.midw.2019.102599 · Cited by 15
Kelley, D. P., Singleton, S. P., Venable, K. E., Sturm, G., Skovgaard, A., Francis, J., Neylan, T. C., Bradley, E., Woolley, J. D., Picard, M. A., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106419 · Cited by 14
The Management of Prodromal Symptoms of Bipolar Disorder: Available Options and Future Perspectives
Favero, E. D., Montemagni, C., Bozzatello, P., Brasso, C., Riccardi, C., & Rocca, P. (2021) · Medicina · doi:10.3390/medicina57060545 · Cited by 12
New Pharmacological Interventions in Bipolar Disorder
Juruena, M. F., Jelen, L. A., Young, A. H., & Cleare, A. J. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_181 · Cited by 10
The major biogenic amine metabolites in mood disorders
Yang, H. J., Yuan, M., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1460631 · Cited by 8
Fares, B. J., Zhou, C., Fabiano, N., Wong, S., Stubbs, B., Shorr, R., Puder, D., Candow, D. G., Ostojić, S. M., & Solmi, M. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251408171 · Cited by 8
Bio, D. S., Moreno, R. A., Garcia-Otaduy, M. C., Nery, F. G., Lafer, B., & Soeiro‐de‐Souza, M. G. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110233 · Cited by 7
Self-citationCreatine prevents ouabain-induced manic-like behavior by modulating GSK-3β via PI3K/AKT/mTOR pathway
Souza-Pereira, A., Guerra, J. M. D. S., Nieswald, B. H., Maidana, L. M., Correa, A. B., Godinho, D. B., Royes, L. F. F., & Rambo, L. M. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174115 · Cited by 6
Creatine supplementation for treating symptoms of depression: a systematic review and meta-analysis
Eckert, I. D. C., Lima, J., & Dariva, A. A. (2025) · British Journal Of Nutrition · doi:10.1017/s0007114525105588 · Cited by 6
Creatine Supplementation and the Brain: Have We Put the Cart Before the Horse?
Candow, D. G., Pratt, J., Fabiano, N., Gordji-Nejad, A., Smith, A., Rawson, E. S., Moriarty, T. A., Forbes, S. C., & Kerksick, C. M. (2026) · Journal of Dietary Supplements · doi:10.1080/19390211.2026.2616440 · Cited by 6
Maiti, R., Mishra, A., Mishra, B. R., & Jena, M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06019-y · Cited by 6
Fornaro, M., Lorenzo, C. D., Oliva, V., Prisco, M. D., & Vieta, E. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122160 · Cited by 4
Zaki, J. K., Tomasik, J., McCune, J. A., Scherman, O. A., & Bahn, S. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08133-7 · Cited by 4
The significance of dysregulated serine metabolism in depression
Lu, Y., Lv, M., Zhao, C., Pei, J., & Zhou, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118458 · Cited by 3
Supplementation of creatine and its role in brain function
Abod, L., Ilnicka, N., Matyja, D., Sadlik, M., & Zuziak, P. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.15.01.017 · Cited by 3
Cuomo, A., Koukouna, D., Pardossi, S., Pinzi, M., Pierini, C., Rescalli, M. B., & Fagiolini, A. (2025) · Pharmacopsychiatry · doi:10.1055/a-2751-7163 · Cited by 2
Suplementación con creatina y cerebro: una revisión narrativa que merece ser valorada
Vargas, J. J. N., & Espinoza, M. A. R. (2022) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.11.01.r0002 · Cited by 2
Application of DPPH assay for the evaluation of the antiradical activity of Creatine Lysinate
Tsvetkova, D. D., Kostadinova, I., Landzhov, B. V., Vezenkov, L., Marinov, L., & Ivanova, I. (2023) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/guimkn4fkf · Cited by 2
Effect of creatine supplementation on women and children/adolescent
Marques, M. V. D. C. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Bury, A., Biesaga, P., Kotte, K., Jadanowski, O., Łebek, K., Sobota, W., Piskorz, P., Litworska-Sójka, D., Komsta, B., & Lipiec, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3546 · Cited by 1
THE ROLE OF CREATINE IN NEUROLOGICAL DISORDERS: A LITERATURE REVIEW
Omidi, A., Ćwiek, M., Malec, K., Krawiec, B., Zarębski, B., Jadanowski, O., Sójka, J., Szombara, M., Mokrzyński, M., & Szyszka, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3722 · Cited by 1
Zimowski, M., Panas, Z., Ślinko, I., Kuliś, G., Dryl-Jarmoc, E., Krawczuk, K., Dziemiańczuk, J., Kadysz, P., Kolanek, A., & Czajkowski, M. (2026) · Quality in Sport · doi:10.12775/qs.2026.55.71160 · Cited by 1
The influence of creatine on brain functioning
Lewandowska, D., Otrębska, K., Makulec, A., Kostecka, N., Jóźwik-Szymańska, A., Mikula, L., Szredzka, A., Bogdan-Groszyk, Z., & Kucharski, J. (2026) · Quality in Sport · doi:10.12775/qs.2026.61.72930 · Cited by 1
THE USE OF CREATINE BEYOND ERGOGENIC POTENTIAL: A NARRATIVE REVIEW
Khouuri, L. M., & Oliveira, R. B. D. A. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594302422036
Messina, D. N., Capone, L. A., & Río, J. A. (2024) · Investigación Ciencia y Universidad · doi:10.59872/icu.v7i8.476
Lifestyle Prescription in Bipolar Disorder: A Systematic Review of Clinical Trials
Ramírez, F. G., Martínez, J. C., Schuch, F. B., Kapczinski, F. P., Boni, R. B. D., & Balanzá‐Martínez, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_41
THERAPEUTIC POTENTIAL OF CREATINE IN PSYCHIATRY: FROM NEUROBIOLOGY TO CLINICAL APPLICATIONS
Gnitecki, S., Wasiak, J., Zielonka, K., Dądela, B., Markowski, M., Śliwa, N., Jakubowska, D., Kawalska, E., Janczura, S., & Borowski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4586
Mooney, J. C., & Bhadha, C. P. (2026) · Cureus · doi:10.7759/cureus.106763
Efectos neuropsiquiátricos de la creatina: ¿Qué concluye la evidencia preclínica y clínica?
Abarca, M., González, A., Dosal, I., de Leon, I., & Arancibia, M. (2026) · Revista médica de Chile · doi:10.4067/s0034-98872026000300430
Creatine supplementation for brain metabolic stress: a narrative review
Candow, D. G., Moriarty, T. A., Wong, S., Fabiano, N., Forbes, S. C., & Kerksick, C. M. (2026) · Academia Neuroscience and Brain Research · doi:10.20935/acadneurosci8345
Szczuciński, W., Polczyk, J. K., Ogorzałek, F. M., Drelich, K., Deptuch, W., Maćko, P. K., Golińska, Z., Zając, M. T., Rajzer, P., & Rurkowska, J. (2026) · Quality in Sport · doi:10.12775/qs.2026.70.74583
Adjunctive nutraceuticals in acute bipolar depression – A systematic review and meta-analysis
Banerjee, P., Kumar, A., Laha, P., Dinakaran, D., Berk, M., & Kesavan, M. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.105171
Fornaro, M., Núñez, N. A., Lorenzo, C. D., Steardo, L., Carvalho, A. F., Singh, B., Veldić, M., Solmi, M., Sambataro, F., Rapaport, M. H., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113881
Peng, T., Lee, M.-C., ISUZUGAWA, K., Lee, J.-A., & Chen, S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122618
Zhao, Y., Zhao, J., Xie, C., Yang, X., & 李建英 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1931736
Perekopskiy, D., Lee, V. M., Pharm, C. T., Caballero, N., & Thackaberry, J. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100354
Cunha, M. P., Akhtar, A. S., & Ramos-Hryb, A. B. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48111174
Creatine Beyond Muscle: Pleiotropic Effects with and Without Exercise—A Critical Narrative Review
Marco-Alacid, C., & Fierro, A. L. (2026) · Nutrients · doi:10.3390/nu18223741
Metadata
- Authors
- Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Toniolo, Ricardo Alexandre
- Venue
- Journal of Neural Transmission
- Published
- 2017-11-24
- Volume
- 125
- Issue
- 2
- Pages
- 247-257
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- PMC
- PMC5775367
- OpenAlex
- W2770274569
- Cited by
- 50
- References
- 55
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 4
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neural Transmission (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (20202)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- creatine monohydrate, bipolar depression, bipolar disorder, adjunctive therapy, mitochondrial dysfunction, brain bioenergetics, nutraceuticals, depression remission, Montgomery-Asberg Depression Rating Scale, subsyndromal depressive symptoms, placebo comparison, mood stabilizers
- MeSH terms
- Proof of Concept Study, Adult, Antidepressive Agents, Antioxidants, Bipolar Disorder, Creatine, Double-Blind Method, Humans, Middle Aged, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.